METHODS OF TREATING BINGE EATING DISORDER
Provided is a method of treating binge eating disorder (BED) in a patient in need thereof comprising administering a therapeutically effective amount of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, to the patient.
1 . A method of treating binge eating disorder in a patient in need thereof comprising administering a therapeutically effective amount of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, to the patient.
2 . A method of treating comorbid binge eating disorder and another psychiatric disorder in a patient in need thereof comprising administering a therapeutically effective amount of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, to the patient.
3 . The method of claim 2 , wherein the other psychiatric disorder is an anxiety disorder, a substance abuse disorder, depression, bipolar disorder, a personality disorder, a somatoform disorder, or attention deficit/hyperactivity disorder.
4 . A method of treating comorbid binge eating disorder and obesity in a patient in need thereof comprising administering a therapeutically effective amount of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, to the patient.
5 . A method of treating comorbid binge eating disorder and fibromyalgia in a patient in need thereof comprising administering a therapeutically effective amount of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, to the patient.
6 . The method of claim 1 , wherein (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane is in pharmaceutically acceptable salt form.
7 . The method of claim 1 , wherein (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in pharmaceutically acceptable salt form is an acid addition salt.
8 . The method of claim 1 , wherein (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in pharmaceutically acceptable salt form is (1R,5 S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride.
9 - 10 . (canceled)
11 . The method of claim 1 , wherein (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, is administered at a dosage of 100 mg to 200 mg.
12 - 13 . (canceled)
14 . The method of claim 11 , wherein (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, is administered once, twice, three, or four times daily.
15 . The method of claim 1 , wherein (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, is administered concurrently or sequentially, in either order, with at least one other therapeutic agent.
16 . The method of claim 15 , wherein the other therapeutic agent is selected from an anti-depressant, an anxiolytic, an anti-obesity agent, and an attention-deficit/hyperactivity disorder agent.
17 . The method of claim 15 , wherein the other therapeutic agent is a second agent that is capable of treating one or more symptoms of binge eating disorder or conditions associated with binge eating disorder.
18 . The method of claim 1 , wherein the patient further undergoes at least one of cognitive behavioral therapy (CBT), interpersonal psychotherapy (IPT), behavioral weight loss treatment (BWL), or dialectical behavior therapy (DBT).
19 . The method of claim 1 , wherein the binge eating disorder comprises 1-3 binge episodes weekly.
20 . The method of claim 1 , wherein the binge eating disorder comprises 4-7 binge episodes weekly.
21 . The method of claim 1 , wherein the binge eating disorder comprises 8-13 binge episodes weekly.
22 . The method of claim 1 , wherein the binge eating disorder comprises 14 or more binge episodes weekly.